Experimental Escherichia coli peritonitis in immunosuppressed mice: the role of specific and nonspecific immunity

References

1. Abernathy R S. 1957; Homologous and heterologous resistance in mice given bacterial endotoxins. Journal of Immunology 78:387–394
   [Google Scholar]
2. Bortolussi R, Ferrieri P. 1980; Protection against Escherichia coli K1 infection in newborn rats by antibody to K1 capsular polysaccharide antigen. Infection and Immunity 28:111–117
   [Google Scholar]
3. Buhles W C, Shifrine M. 1977; Adjuvant protection against bacterial infection in granulocytopenic mice. Journal of Infectious Diseases 136:90–95
   [Google Scholar]
4. Cross A S, Zollinger W, Mandrell R, Gemski P, Sadoff J. 1983; Evaluation of immunotherapeutic approaches for the potential treatment of infections caused by K1-positive Escherichia coli . Journal of Infectious Diseases 147:68–76
   [Google Scholar]
5. Elbein A D, Heath E C. 1965; The biosynthesis of cell wall lipopolysaccaride in Escherichia coli. I. The biochemical properties of a uridine diphosphate galactose-4-epimerase-less mutant. Journal of Biological Chemistry 240:1919–1925
   [Google Scholar]
6. Galanos C, Lüderitz O, Westphal O. 1969; A new method for the extraction of R lipopolysaccharides. European Journal of Biochemistry 9:245–249
   [Google Scholar]
7. Galelli A, Parant M, Chedid L. 1977; Role of radiosensitive and radioresistant cells in nonspecific resistance to infection of LPS-treated mice. Journal of the Reticuloendothelial Society 21:109–118
   [Google Scholar]
8. Harvath L, Andersen B R. 1976; Evaluation of type-specific and non-type-specific Pseudomonas vaccine for treatment of Pseudomonas sepsis during granulocytopenia. Infection and Immunity 13:1139–1143
   [Google Scholar]
9. Hunninghake G W, Fauci A S. 1976; Divergent effects of cyclophosphamide administration on mononuclear killer cells: quantitative depletion of cell numbers versus qualitative suppression of functional capabilities. Journal of Immunology 117:337–342
   [Google Scholar]
10. Kaufman B M, Cross A S, Futrovsky S L, Sidberry H F, Sadoff J C. 1986; Monoclonal antibodies reactive with K1-encapsulated Escherichia coli lipopolysaccharide are op-sonic and protect mice against lethal challenge. Infection and Immunity 52:617–619
    [Google Scholar]
11. Kim K S, Kang J H, Cross A S. 1986; The role of capsular antigens in serum resistance and in vivo virulence of Escherichia coli . FEMS Microbiology Letters 35:275–278
    [Google Scholar]
12. Landy M. 1956; Increase in resistance following administration of bacterial lipopolysaccharides. Annals of the New York Academy of Sciences 66:292–303
    [Google Scholar]
13. Lumish R M, Norden C W. 1976; Therapy of neutropenic rats infected with Pseudomonas aeruginosa . Journal of Infectious Diseases 133:538–547
    [Google Scholar]
14. Miller J H. 1972; Experiments in molecular genetics. Cold Spring Harbor Laboratory; New York:
    [Google Scholar]
15. Nowicki B, Vuopio-Varkila J, Viljanen P, Korhonen T K, Mäkelä P H. 1986; Fimbrial phase variation and systemic E coli infection studies in the mouse peritonitis model. Microbial Pathogenesis 1:335–347
    [Google Scholar]
16. Petursson S R, Chervenick P A. 1982; Megakaryocytopoiesis and granulopoiesis following cyclophosphamide. Journal of Laboratory and Clinical Medicine 100:682–694
    [Google Scholar]
17. Pierson C L, Johnson A G, Feller I. 1976; Effect of cyclophosphamide on the immune response to Pseudomonas aeruginosa in mice. Infection and Immunity 14:168–177
    [Google Scholar]
18. Pluschke G, Achtman M. 1985; Antibodies to O-antigen of lipopolysaccharide are protective against neonatal infection with Escherichia coli K1. Infection and Immunity 49:365–370
    [Google Scholar]
19. Reed L J, Muench H. 1938; A simple method of estimating fifty per cent end-points. American Journal of Hygiene 27:493–497
    [Google Scholar]
20. Saxén H, Mäkelä O. 1982; The protective capacity of immune sera in experimental mouse salmonellosis is mainly due to IgM antibodies. Immunology Letters 5:267–272
    [Google Scholar]
21. Swinscow T D V. 1978; Statistics at square one. , 4. British Medical Association; London:54–57
    [Google Scholar]
22. Tatsukawa K, Mitsuyama M, Takeya K, Nomoto K. 1979; Differing contribution of polymorphonuclear cells and macrophages to protection of mice against Listeria mono-cytogenes and Pseudomonas aeruginosa . Journal of General Microbiology 115:161–166
    [Google Scholar]
23. Tegtmeier B R, Andersen B R. 1983; Mechanisms of lipopolysac-charide-induced protection against Pseudomonas sepsis in granulocytopenic mice. Reviews of Infectious Diseases 5:S963–S970
    [Google Scholar]
24. Trautmann M, Müller-Leutloff Y, Hofstaetter T, Seiler F R, Hahn H. 1985; Experimental Klebsiella septicaemia in mice: treatment with specific antibodies from the rabbit alone and in combination with gentamicin. Infection 13:29–34
    [Google Scholar]
25. Tsuru S, Nomoto K, Mitsuyama M, Zinnaka Y, Takeya K. 1981; Importance of polymorphonuclear leucocytes in protection of mice against Escherichia coli . Journal of General Microbiology 122:335–338
    [Google Scholar]
26. Turk J L, Parker D. 1982; Effect of cyclophosphamide on immunological control mechanisms. Immunological Reviews 65:99–113
    [Google Scholar]
27. Van der Ley P, Kuipers O, Tommassen J, Lugtenberg B. 1986; O-antigenic chains of lipopolysaccharide prevent binding of antibody molecules to an outer membrane pore protein in Enterobacteriaceae. Microbial Pathogenesis 1:43–49
    [Google Scholar]
28. Vuopio-Varkila J, Karvonen M, Saxen H. 1988a; The protective capacity of antibodies to various outer membrane components in a systemic mouse peritonitis model caused by Escherichia coli O18:K1. Journal of Medical Microbiology. In press
    [Google Scholar]
29. Vuopio-Varkila J, Nurminen M, Phyälä L, Mäkelä P H. 1988b; LPS-induced nonspecific resistance to systemic Escherichia coli infection in mice. Journal of Medical Microbiology. In press
    [Google Scholar]
30. Weinstein M P, Murphy J R, Reller L B, Lichtenstein K A. 1983a; The clinical significance of positive blood cultures: a comprehensive analysis of 500 episodes of bacteremia and fungemia in adults. II. Clinical observations with special reference to factors influencing prognosis. Reviews of Infectious Diseases 5:54–70
    [Google Scholar]
31. Weinstein M P, Reller L B, Murphy J R, Lichtenstein K A. 1983b; The clinical significance of positive blood cultures: a comprehensive analysis of 500 episodes of bacteremia and fungemia in adults. I. Laboratory and epidemiologic observations. Reviews of Infectious Diseases 5:35–53
    [Google Scholar]